Syros Pharmaceuticals (NASDAQ:SYRS) Given “Neutral” Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report published on Wednesday, MarketBeat Ratings reports. HC Wainwright currently has a $1.00 target price on the stock, down from their prior target price of $6.00. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q1 2025 earnings at ($0.70) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.69) EPS.

Several other research analysts have also recently weighed in on SYRS. Piper Sandler reissued an “overweight” rating and set a $5.00 price target (down previously from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday. JMP Securities reduced their price target on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, StockNews.com lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, Syros Pharmaceuticals presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.26 on Wednesday. The stock has a 50 day moving average of $2.02 and a two-hundred day moving average of $3.79. Syros Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $8.17. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. The firm has a market cap of $6.96 million, a P/E ratio of -0.09 and a beta of 1.59.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period last year, the firm posted ($1.35) earnings per share. On average, analysts expect that Syros Pharmaceuticals will post -2.99 earnings per share for the current fiscal year.

Insider Activity

In other Syros Pharmaceuticals news, CEO Conley Chee purchased 50,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was acquired at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the purchase, the chief executive officer now directly owns 72,504 shares in the company, valued at approximately $109,481.04. The trade was a 222.18 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jason Haas acquired 35,363 shares of Syros Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was bought at an average price of $1.55 per share, for a total transaction of $54,812.65. Following the completion of the purchase, the chief financial officer now owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. This represents a 144.03 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 130,707 shares of company stock valued at $206,491. 12.26% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Opaleye Management Inc. grew its position in shares of Syros Pharmaceuticals by 119.1% during the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock worth $4,213,000 after buying an additional 428,175 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in Syros Pharmaceuticals in the first quarter worth approximately $2,166,000. Vanguard Group Inc. grew its holdings in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares in the last quarter. Certuity LLC purchased a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at approximately $109,000. Finally, Acadian Asset Management LLC lifted its position in shares of Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.